| Oct 30 |
Bausch Health up 5.5% in New York Trade as It Reports a Higher Adjusted Third-Quarter Profit, Ups Guidance
|
| Oct 30 |
Bausch Health Announces Third Quarter 2024 Results
|
| Oct 30 |
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
| Oct 30 |
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates
|
| Oct 30 |
Bausch + Lomb: Q3 Earnings Snapshot
|
| Oct 27 |
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
|
| Oct 23 |
Bausch Health (BHC) Reports Next Week: What to Expect
|
| Oct 22 |
Bausch + Lomb Q3 Report Likely to Focus on Potential Sale, Dry Eye Disease Drugs, RBC Says
|
| Oct 21 |
Banks, Private Credit Vie for $5 Billion Bausch + Lomb Debt
|
| Oct 19 |
Bausch Health call volume above normal and directionally bullish
|
